Related Experiment Video
Updated: Dec 6, 2025
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.9K
Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma.
Shebli Atrash1, Syed Abbas Ali2, Saad Z Usmani1
1Plasma Cell Disorders Division, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.
Clinical Lymphoma, Myeloma & Leukemia
|October 13, 2020
Summary
Chimeric antigen receptor (CAR)-T cell therapy shows promise for relapsed/refractory multiple myeloma (MM). Research is advancing CAR-T cells targeting B-cell maturation antigen for MM treatment.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Relapsed/refractory multiple myeloma (MM) presents a significant therapeutic challenge.
- Immunotherapy, particularly chimeric antigen receptor (CAR)-T cells, has revolutionized hematologic malignancy treatment.
- CAR-T cell therapy has recently demonstrated therapeutic benefit in MM, with ongoing rapid development.
Purpose of the Study:
- To provide an updated review of clinical trials involving multiple myeloma-specific CAR-T cells.
- To highlight the potential of CAR-T cell therapy in treating relapsed/refractory MM.
- To discuss the complexities and advancements in CAR-T cell therapy for MM.
Main Methods:
- Review of current clinical trials for MM-specific CAR-T cells.
- Analysis of CAR-T cell platform advancements for MM.
- Discussion of target antigen identification and CAR construct optimization.
Main Results:
- CAR-T cells targeting CD-19 have shown efficacy in other hematologic malignancies.
- The B-cell maturation antigen is a primary target for MM CAR-T cell therapy.
- CAR-T cell therapy is a rapidly progressing and promising modality for MM treatment.
Conclusions:
- CAR-T cells hold immense therapeutic promise for multiple myeloma.
- Ongoing research focuses on identifying specific tumor antigens and optimizing CAR constructs to minimize toxicities like cytokine release syndrome.
- This review summarizes the latest clinical trial data for MM-specific CAR-T cells.
